论文部分内容阅读
以２．２．１５细胞为靶细胞，研究靶向药物（单磷酸阿糖腺苷与半乳糖化人血清白蛋白交联物）的体外抗病毒作用，同时对拟选作交联用的某些植物毒素蛋白等进行了体外筛选。结果表明，交联物与单用Ａｒａ－ＡＭＰ有大致相同的抗乙型肝炎病毒作用。交联物（按Ａｒａ－ＡＭＰ计算）１２５～２００ｍｇ／ｍ１，均有轻度到明显抗乙型肝炎病毒作用（除１２．５ｍｇ／ｍｌ作用５ｄ外），治疗指数以１０～２０ｄ为最高。木鳖子素５～４０ｍｇ／ｍｌ有轻度到明显抗病毒作用，对ＨＢｓＡｇ或ＨＢｅＡｇ的治疗指数分别达到２．６和５．９，本组靶向药物有进一步研究价值
2.2.15 cells as target cells to study the targeted drug (monophosphate arabinoside and galactosylated human serum albumin cross-linked material) in vitro antiviral effect, while the proposed for the cross-linked with a Some plant toxin proteins were screened in vitro. The results show that the cross-linked substance has substantially the same anti-hepatitis B virus effect as Ara-AMP alone. The conjugate (calculated as Ara-AMP) 125 ~ 200mg / m1, mild to significant anti-hepatitis B virus effect (except 12.5mg / ml effect 5d), the treatment index to 10 ~ 20d for the highest. Momordicin 5 ~ 40mg / ml mild to significant antiviral effect, the HBsAg or HBeAg treatment index reached 2.6 and 5.9, respectively, the group of targeted drugs have further research value